Stay updated with breaking news from Immunocore Imm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp to be presented during oral abstract...
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK net revenues of $67.6 million in Q4 2023 and $238.7 million in 2023; increasing...
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update KIMMTRAK (tebentafusp) net revenues of $67.6...